Veklury® (remdesivir)

Covered: Veklury (remdesivir) is authorized for adults and pediatric patients (birth to <18 years) weighing ≥1.5 kg with mild-to-moderate COVID‑19 who are at high risk for progression, limited to a single 3‑day IV course with specified weight- and age‑based dosing; excluded are patients <1.5 kg, those without a positive SARS‑CoV‑2 test, and (per this policy) treatment of severe COVID‑19. Key requirements: must have a positive SARS‑CoV‑2 test, documented age and weight (to determine dosing), clinical documentation of mild‑to‑moderate disease and high‑risk status, and medication orders/infusion records consistent with the 3‑day IV regimen.

"Indication limited to mild-to-moderate COVID-19 (not described as authorized for severe COVID-19 in this document)."

Sign up to see full coverage criteria, indications, and limitations.